We accompanied the dissemination day of the CASMU Hemocenter in relation to the recently incorporated inactivation of pathogens in CERUS blood components.
Once the stage of staff training and review of the technology has been completed, the blood center focuses on the dissemination of this information so that doctors and graduates in hemotherapy and other specialties in Uruguay know that it is located in the country and is accessible.
On behalf of CERUS, Claudia Burgos shared the company's international experience both in terms of benefits for patients and at the economic level of medical institutions. In addition to the broad-spectrum protection of patients through the inactivation of bacteria, viruses, protozoa, leukocytes and emerging pathogens, the operational efficiency of this solution was discussed: it increases the shelf life of blood components, makes CMV serology and irradiation unnecessary, avoids the discarding of products, etc.
On behalf of CASMU, Dr. Ferrari, head of the blood center, commented that "we are producing platelet concentrates of the best quality available and this incorporation speaks of the commitment we have with transfusion quality. A commitment that is born because through transfusions we can contribute to making the difference in the patient between life and death. That is why we aspire to the universalization of inactivation."
With pride, Burgos points out that "Uruguay is the first country in South America to implement the inactivation of pathogens with Intercept, let's be the ones who leave the mark for others to follow and make transfusion medicine an increasingly safe experience for everyone. It is in our hands to take advantage of what science provides us."
